TLC 6740
Alternative Names: TLC-6740Latest Information Update: 25 Jun 2025
At a glance
- Originator Gilead Sciences
- Developer OrsoBio
- Class Antihypercalcaemics; Hepatoprotectants; Obesity therapies
- Mechanism of Action Mitochondrial oxidative phosphorylation uncouplers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus; Lipodystrophy; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 20 Jun 2025 Pharmacodynamics data from a preclinical trial in Obesity released by OrsoBio
- 09 Sep 2024 Pharmacodynamics data from a preclinical trial in Obesity presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)
- 09 Sep 2024 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Type 2 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)